Actually, iNOS has been emphasized in GBM pathogenesis by the fact that inhibition of iNOS by genetic and pharmacological approaches impedes glial cell proliferation, invasiveness, and tumor growth in vivo [33], and that repression of GBM iNOS in vivo leads to a reduction in both microglia recruitment and tumor expansion [34]. This evidence concerns the gene NOS2 and neoplasm.